Johnson & Johnson's stock trajectory hinges on two pending FDA approvals following this year's successful clearances for Icotyde and Rybrevant. The psoriasis and lung cancer therapies propelled JNJ shares 11.5% year-to-date, peaking at $248 in March before settling at $230 this week.

Regulatory scrutiny now shifts to the Ottava robotic surgery system and experimental drug JNJ-78934804. The former awaits final FDA review while the latter remains in clinical trials. Market analysts view these decisions as inflection points—approval could extend JNJ's 2026 pharmaceutical breakout, while rejection may pressure recent gains.

Investors are pricing in a 60-70% probability of success for both applications according to options market activity. The Ottava system particularly represents a paradigm shift in minimally invasive procedures, with Wall Street estimating $4-7 billion in peak sales should it clear regulatory hurdles.